Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The CYP2D6 metaboliser status of patients prescribed risperidone for the treatment of psychosis.

The New Zealand medical journal - 5 Jun 2009

Dunbar Lucy, Miles Wayne, Wheeler Amanda, Sheridan Janie, Pulford Justin, Butler Rachael

Abstract excerpt

AIM: To identify the distribution of CYP2D6 metaboliser status in patients who were being prescribed risperidone for the treatment of psychosis in a New Zealand-based clinical population. METHOD: 100 AmpliChip CYP450 Test kits were made available by Roche Diagnostics. Clinicians in mental health services across three Auckland District Health Boards were instructed that the tests were being made available for use...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to New Zealand

Share to Polymorphism, Genetic

Share to Psychotic Disorders

Share to Risperidone

Share to White People

Source

Identifiers

PMID: 19652678

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The CYP2D6 metaboliser status of patients prescribed risperidone for the treatment of psychosis.PMID 19652678Read ↗

The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.Semantic proximity Read ↗

Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.Semantic proximity Read ↗

Into a Deeper Understanding of CYP2D6's Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders.Semantic proximity Read ↗

Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone.Semantic proximity Read ↗

Clinical effects of CYP2D6 phenoconversion in patients with psychosis.Semantic proximity Read ↗

Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional StudySemantic proximity Read ↗

CYP2D6 polymorphisms and their influence on risperidone treatmentSemantic proximity Read ↗

Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users.Semantic proximity Read ↗

Risperidone plasma levels, clinical response and side-effects.Semantic proximity Read ↗

CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study.Semantic proximity Read ↗

The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.Semantic proximity Read ↗

Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.